Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors
03 Oktober 2024 - 10:00PM
Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), the Spatial
Biology Company®, today announced Scott Mendel has been appointed
as Chairman of its Board, effective October 2, 2024. Mr. Mendel
succeeds Robert Shepler, founding Chairman, who will remain on
Akoya’s board. Mr. Mendel has served as a member of Akoya’s board
of directors since June 2021 and has over 30 years of financial and
operational management experience.
“I am thrilled to continue working with Akoya’s Management Team
to capitalize on the Company’s leadership position in Spatial
Biology. I intend to leverage my public company experience to
assist in delivering on Akoya’s potential and maximizing
shareholder return,” said Mr. Mendel.
Mr. Mendel, a leader in the diagnostics industry, previously
served as President and Chief Executive Officer and a member of the
board of directors of GenMark Diagnostics, Inc., a publicly traded
molecular diagnostics company, from May 2020 until its acquisition
by Roche in April 2021 for $1.8 billion. From May 2014 to May 2020,
Mr. Mendel also served in various roles of ascending responsibility
with GenMark, including as interim Chief Executive Officer, Chief
Operating Officer and Chief Financial Officer. Before GenMark, Mr.
Mendel served as the Chief Financial Officer of The Active Network,
Inc., a publicly traded global SaaS company that provided
technology to organizers of events and activities, from March 2010
through its acquisition in November 2013 by Vista Equity Partners.
Prior to joining The Active Network, Mr. Mendel held finance
positions at General Electric for over 20 years, including Chief
Financial Officer from March 2003 to March 2010 of General
Electric’s Healthcare IT division, a leading provider of medical
technologies and services. Mr. Mendel has served on the board of
Quantum-Si Incorporated, a public protein sequencing company, since
May 2023 and serves as a director of Pattern Biosciences, a company
focused on rapid pathogen identification and antibiotic
susceptibility test (AST).
“Having been involved with Akoya since its start-up in 2015 as
one of its founding investors and a board member, I felt it was
time to transition the Chairman’s role to such a talented executive
as Scott. I am proud of what the Akoya team has achieved to date
and very excited about its future prospects with Scott’s leadership
as Chairman,” said Mr. Shepler.
“Scott’s long and successful history of operational leadership,
coupled with his experience advising multiple companies in the
tools and diagnostics industry makes him an ideal person for this
role. I look forward to working even more closely with Scott to
continue to ensure Akoya makes a positive impact for all
stakeholders,” said Brian McKelligon, CEO of Akoya Biosciences.
Forward-Looking Statements
This press release contains forward-looking statements that are
based on management’s beliefs and assumptions and on information
currently available to management. All statements contained in this
release other than statements of historical fact are
forward-looking statements, including statements regarding our
prospects, our position in the spatial biology market, our ability
to maximize shareholder return and other statements regarding our
business strategies, results of operations, performance and plans
and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is
to bring context to the world of biology and human health through
the power of spatial phenotyping. The Company offers comprehensive
single-cell imaging solutions that allow researchers to phenotype
cells with spatial context and visualize how they organize and
interact to influence disease progression and response to therapy.
Akoya offers a full continuum of spatial phenotyping solutions to
serve the diverse needs of researchers across discovery,
translational and clinical research: PhenoCode™ Panels and
PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments.
To learn more about Akoya, visit www.akoyabio.com.
Investor Contact:
Priyam Shah
investors@akoyabio.com
Media Contact:
Christine Quern
media@akoyabio.com
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
Von Dez 2023 bis Dez 2024